Nuyten Dimitry SA 4
4 · Arcus Biosciences, Inc. · Filed Dec 20, 2023
Insider Transaction Report
Form 4
Nuyten Dimitry SA
Chief Medical Officer
Transactions
- Disposition to Issuer
Common Stock
2023-12-19$18.09/sh−1,540$27,859→ 71,195 total - Disposition to Issuer
Common Stock
2023-12-18$17.74/sh−1,507$26,734→ 72,735 total
Footnotes (4)
- [F1]Represents shares sold by the issuer on the reporting person's behalf to cover tax withholding obligations in connection with the vesting of certain RSUs (previously reported in Table I) following the date of grant. The sale occurred automatically pursuant to the Issuer's equity administration policy, which was implemented on January 15, 2021, and does not represent a discretionary trade by the reporting person.
- [F2]The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.45 to $17.95, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- [F3]Includes 651 shares purchased on 11/30/2023 through the Company's Employee Stock Purchase Plan.
- [F4]The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.78 to $18.24, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.